Abstract
In previous open studies, misoprostol and metronidazole reduced nonsteroidal anti-inflammatory drug-induced intestinal permeability changes and inflammation respectively. We assessed the effects of indomethacin treatment (50 mg three times a day) for one week with either coadministered metronidazole (400 mg twice a day, group 1,N=9) or misoprostol (200 μg four times a day, group 2,N=7) on intestinal permeability to [51Cr]EDTA and mannitol in healthy volunteers, using double-blind, placebo-controlled, randomized techniques. Given alone, neither metronidazole nor misoprostol affected [51Cr]EDTA permeation, whereas indomethacin alone increased it from 1.20 (0.40) [mean percent urinary recovery (sd) groups 1 and 2] to 2.43 (0.72),P<0.002. Coadministered metronidazole (group 1) prevented this increase [1.10 (0.39) before, 1.55 (0.54) after,P>0.05], whereas misoprostol (group 2) did not [1.31 (0.51) before, 3.26 (1.10) after,P=0.005]. No drug regimen altered mannitol permeation. Indomethacin and misoprostol did not affect urinary recovery of intravenously administered probes. The results with metronidazole, if related to its antibacterial effects, support evidence from animal models that bacteria contribute to NSAID-induced intestinal damage. The previously reported reduction of indomethacin-induced increased permeability by misoprostol during a one-day study is not seen when the drugs are used in standard clinical doses for one week.
Similar content being viewed by others
References
Davies GR, Rampton DS: The pro-drug sulindac may reduce the risk of intestinal damage associated with the use of conventional non-steroidal antiinflammatory drugs. Aliment Pharmacol Ther 5:593–598, 1991
Bjarnason I, Fehilly B, Smethurst P, Menzies IS, Levi AJ: Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut 32:275–277, 1991
Bjarnason I, So A, Levi AJ, Peters TJ, Williams P, Zanelli GD, Gumpel JM, Ansell B: Intestinal permeability and inflammation in rheumatoid arthritis: Effects of non-steroidal anti-inflammatory drugs. Lancet ii:1171–1174, 1984
Jenkins RT, Rooney PJ, Jones DB, Bienenstock, J, Goodacre RL: Increased intestinal permeability in patients with rheumatoid arthritis: A side effect of oral nonsteroidal anti-inflammatory drug therapy? Br J Rheumatol 26:103–107, 1987
Morris AJ, Madhok R, Sturrock RD, Capell HA, MacKenzie JF: Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs. BMJ 337:520, 1991
Bjarnason I, Peters TJ: Intestinal permeability, non-steroidal antiinflammatory drug enteropathy and inflammatory bowel disease: An overview. Gut Festschrift 30:22–28, 1989
Rampton DS: Nonsteroidal antiinflammatory drugs and the lower gastrointestinal tract. Scand J Gastroenterol 22:1–4, 1987
Sartor RB: Importance of intestinal mucosal immunity and luminal bacterial cell wall polymers in the aetiology of inflammatory joint disease.In Baillières Clinical Rheumatology. PJ Rooney (ed). London, Baillière-Tindall, 1989, pp 223–245
Zaphiropoulos GC: Rheumatoid arthritis and the gut. Br J Rheumatol 25:138–140, 1986
Bourne JT, Kumar P, Huskisson EC, Mageed R, Unsworth DJ, Wojtulewski JA: Arthritis and coeliac disease. Ann Rheum Dis 44:592–598, 1985
Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, Levi AJ: Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci 34:407–411, 1989
Bjarnason I, Smethurst P, Clark P, Menzies I, Levi J, Peters T: Effect of prostaglandin on indomethacin inceased intestinal permeability in man. Scand J Gastroenterol (Suppl) 164:97–103, 1989
Bjarnason I, Williams P, Smethurst P, Peters TJ, Levi AJ: Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 27:1292–1297, 1986
Rooney PJ, Jenkins RT: Nonsteroidal antiinflammatory drugs (NSAIDs) and the bowel mucosa: Changes in intestinal permeability may not be due to changes in prostaglandins. Clin Exp Rheum 8:328–329, 1990
Hallyar J, Somasundaram S, Sarathchandra P, Levi AJ, Bjarnason I: Early cellular events in the pathogenesis of NSAID enteropathy in the rat. Gastroenterology 100:A216, 1991
Bjarnason I: Non-steroidal anti-inflammatory drug-induced small intestinal inflammation in man.In Recent Advances in Gastroenterology, RE Pounder (ed). London, Churchill Livingstone, 1989, pp 23–46.
Rainsford KD: Mechanisms of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol (Suppl) 163:9–16, 1989
Rainsford KD: Mechanisms of gastric contrasted with intestinal damage by non-steroidal anti-inflammatory drugs.In Side Effects of Anti-Inflammatory Drugs: Part 2. KD Rainsford, GP Velo (eds). Lancaster, UK, MTP Press, 1987, pp 3–28
Jenkins AP, Trew DR, Crump BJ, Nukajam WS, Foley JA, Menzies IS, Creamer B: Do non-steroidal anti-inflammatory drugs increase colonic permeability? Gut 32:66–69, 1991
Kent TH, Cardelli RM, Stamler FW: Small intestinal ulcers in rats given indomethacin. Am J Pathol 54:237–245, 1969
Robert A, Asano T: Resistance of germ free rats to indomethacin-induced intestinal lesions. Prostaglandins 14:331–341, 1977
Bjarnason I, Hallyar J, Smethurst P, Price A, Gumpel M, Levi J: Studies on the pathogenesis of non-steroidal anti-inflammatory drug (NSAID) induced enteropathy in man. Gastroenterology 100:A198, 1991
Bjarnason I, Hopkinson N, Zanelli G, Prouse P, Smethurst P, Gumpel JM, Levi AJ: Treatment of non-steroidal anti-inflammatory drug induced enteropathy. Gut 33:777–780, 1990
Bjarnason I, Ward K, Peters TJ: The leaky gut of alcoholism: Possible route of entry for toxic compounds. Lancet i:179–182, 1984
Bjarnason I, Levi S, Smethurst P, Menzies IS, Levi AJ: Vindaloo and you. BMJ 297:1629–1631, 1988
Laker MF, Gunn WG: Natural occurrence disqualifies manitol as an internal standard when urinary monosaccharides are determined by gas liquid chromatography. Clin Chim Acta 96:265–267, 1979
Laker MF, Mount JN: Mannitol estimation in biological fluids by gas-liquid chromatography of trimethylsilyl derivatives. Clin Chem 26:441–443, 1980
Blood J, Ingle AR, Allinson N, Davies GR, Hill PG: Rapid enzymatic method for measurement of mannitol in urine. Ann Clin Chem 28:401–406, 1991
Robert A: An intestinal disease produced experimentally by a prostaglandin deficiency. Gastroenterology 69:1045–1047, 1975
Del Soldato P, Foschi D, Benoni G, Scarpignato C: Oxygen free radicals interact with indomethacin to cause gastrointestinal injury. Agents Actions 17:484–488, 1985
Akamatsu H, Oguchi M, Nishijima S, Asada Y, Takahashi M, Ushijima T, Niwa Y: The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: A possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res 282:449–454, 1991
Miyachi Y, Yoshioka A, Imamura S, Niwa Y: Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut 28:190–195, 1987
Grove DI, Mahmoud AF, Warren KS: Suppression of cell-mediated immunity by metronidazole. Int Arch Allergy Appl Immunol 54:422–427, 1977
Helleberg L: Clinical pharmacokinetics of indomethacin. Clin Pharmacokinet 6:245–258, 1981
Duggan DE, Hooke KF, Noll RM, Kwan KC: Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem Pharmacol 25:1749–1754, 1975
Scoenhard G, Opperman J, Kohn FE: Metabolism of and pharmacokinetic studies of misoprostol. Dig Dis Sci 30:126S-128S, 1985
Steiner JA: Misoprostol clinical pharmacokinetics. Dig Dis Sci 30:136S-141S, 1985
Isselbacher KJ: The role of arachidonic acid metabolites in gastrointestinal homeostasis. Biochemical, histological and clinical effects. Drugs 33 (suppl 1):38–46, 1983
Yamada T, Specian RD, Granger DN, Gaginella TS, Grisham MB: Misoprostol attenuates acetic acid-induced increases in mucosal permeability and inflammation: Role of blood flow. Am J Physiol 261:G332-G339, 1992
Patrono C: Pharmacologic modulation of the cyclooxygenase pathway in the human kidney. Adv Prostaglandin Thromboxane Leukotriene Res 20:250–256, 1990
Author information
Authors and Affiliations
Additional information
Dr. Davies is partly supported by a grant from Searle and Dr. Wilkie by a grant from Bayer.
Rights and permissions
About this article
Cite this article
Davies, G.R., Wilkie, M.E. & Rampton, D.S. Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability. Digest Dis Sci 38, 417–425 (1993). https://doi.org/10.1007/BF01316493
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01316493